UBS Group’s American Renal Associates Holdings, Inc ARA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-4,165
| Closed | -$47K | – | 9918 |
|
|
2020
Q4 | $47K | Buy |
4,165
+3,045
| +272% | +$34.7K | ﹤0.01% | 6252 |
|
|
2020
Q3 | $7K | Sell |
1,120
-4,201
| -79% | -$27.6K | ﹤0.01% | 7180 |
|
|
2020
Q2 | $35K | Sell |
5,321
-6,633
| -55% | -$42.8K | ﹤0.01% | 6182 |
|
|
2020
Q1 | $79K | Sell |
11,954
-12,211
| -51% | -$106K | ﹤0.01% | 5482 |
|
|
2019
Q4 | $251K | Buy |
24,165
+9,909
| +70% | +$84.7K | ﹤0.01% | 5439 |
|
|
2019
Q3 | $90K | Buy |
14,256
+7,934
| +125% | +$59.1K | ﹤0.01% | 5832 |
|
|
2019
Q2 | $47K | Buy |
6,322
+4,422
| +233% | +$29.2K | ﹤0.01% | 5985 |
|
|
2019
Q1 | $12K | Sell |
1,900
-5,622
| -75% | -$65.1K | ﹤0.01% | 6714 |
|
|
2018
Q4 | $87K | Buy |
7,522
+411
| +6% | +$7.01K | ﹤0.01% | 5650 |
|
|
2018
Q3 | $154K | Buy |
7,111
+3,273
| +85% | +$61.9K | ﹤0.01% | 5249 |
|
|
2018
Q2 | $60K | Buy |
3,838
+3,468
| +937% | +$54.5K | ﹤0.01% | 5847 |
|
|
2018
Q1 | $7K | Sell |
370
-524
| -59% | -$10.3K | ﹤0.01% | 7109 |
|
|
2017
Q4 | $16K | Buy |
894
+566
| +173% | +$7.81K | ﹤0.01% | 6743 |
|
|
2017
Q3 | $5K | Sell |
328
-1,343
| -80% | -$21.1K | ﹤0.01% | 7258 |
|
|
2017
Q2 | $31K | Sell |
1,671
-707
| -30% | -$12.3K | ﹤0.01% | 6003 |
|
|
2017
Q1 | $40K | Buy |
2,378
+222
| +10% | +$4.43K | ﹤0.01% | 5689 |
|
|
2016
Q4 | $46K | Buy |
+2,156
| New | +$44.2K | ﹤0.01% | 5895 |
|
|
2016
Q3 | – | Sell |
-1,343
| Closed | -$39K | – | 8074 |
|
|
2016
Q2 | $39K | Buy |
+1,343
| New | +$37.4K | ﹤0.01% | 5719 |
|
UBS Group's ARA Position: Q1 2021 in Review
UBS Group sold out of American Renal Associates Holdings, Inc (ARA) in Q1 2021, closing a stake of 4,165 shares — an estimated $47K sold.
UBS Group first reported a position in ARA in Q2 2016 and held it in 18 quarters. The position peaked at $251K in Q4 2019. 0 funds tracked by Wall St. Rank hold ARA as of Q1 2021.
- UBS Group reported no remaining American Renal Associates Holdings, Inc position as of Q1 2021 after selling out during the quarter.
- UBS Group sold 4,165 American Renal Associates Holdings, Inc shares in Q1 2021, an estimated $47K.
- UBS Group first reported a position in American Renal Associates Holdings, Inc in Q2 2016 and held it in 18 quarters.
- UBS Group's American Renal Associates Holdings, Inc position peaked at $251K in Q4 2019.
- 0 funds tracked by Wall St. Rank held American Renal Associates Holdings, Inc as of Q1 2021.
Based on UBS Group's 13F filing for Q1 2021, filed 12 May 2021.